Our Leadership
Meet The Team Behind The Innovation
Gary A. Shangold, MD FACOG,
Founder & Chief Executive Officer
-
Dr. Shangold is a Founder and the CEO of InteguRx Therapeutics. He brings more than 30 years of pharmaceutical industry and consulting experience in clinical research, regulatory affairs, and general management to the role. A seasoned industry professional, he has held C-suite level roles at a variety of innovative organizations. Recent engagements include serving as the Chief Medical Officer for 3Daughters and Enteris BioPharma, and before that for Xanodyne Pharmaceuticals. Dr. Shangold is the Founder and Managing Member of Convivotech, a consultancy to Life Sciences companies. Prior to those roles, he was President & CEO of NovaDel Pharma, a publicly-traded specialty pharma company [AMEX:NVD]. Earlier still, Dr. Shangold held several senior roles at Johnson & Johnson Pharmaceutical R&D, including Vice President & Regulatory Head of Drug Development, Contraception Global Product Leader, and Senior Director of Gynecologic & Reproductive Clinical Research. Before J&J, Shangold was the Medical Director for Obstetrics/Gynecology/Infertility at Serono Laboratories Inc, then the US affiliate of Ares-Serono.
Prior to his full-time career in industry, Dr. Shangold served on the faculties of The University of Chicago Pritzker School of Medicine, Massachusetts General Hospital and the Harvard School of Medicine. He is a Past President of the American Academy of Pharmaceutical Physicians and a former Board Chair of the Association of Clinical Research Professionals.
Dr. Shangold completed an Ob/Gyn residency at Jackson Memorial Hospital / University of Miami and a fellowship in Reproductive Endocrinology at the Los Angeles County / University of Southern California Medical Center; he is Board Certified in Obstetrics & Gynecology and Reproductive Endocrinology. He received a Bachelor of Arts in Social Behavior from the University of Pennsylvania, and his MD from Columbia University’s College of Physicians and Surgeons.
Agis Kydonieus, PhD,
Co-Founder & Chief Scientific Officer
-
Dr. Kydonieus is a Founder and the Chief Scientific Officer of InteguRx Therapeutics. His career spans more than 40 years of experience in the field of drug delivery in general, and he was one of the pioneers in the science of transdermal drug delivery specifically. He is the President of Samos Pharmaceuticals, a consultancy in drug delivery and biomaterials development, through which he has consulted to a number of innovative startups over the years -- including such entities as Agile Therapeutics [NASDAQCM:AGRX], Kore Therapeutics, and Arkayli Biopharma – and he has played a significant role in helping to bring a number of transdermal products to the market; these include a nitroglycerin patch, a contraceptive patch (Twirla®), and a product for bladder cancer (Valstar®). Earlier in his career he was the Vice President of Research at Bristol Myers Squibb, and before that he was the Co-Founder and President of two startup companies in transdermal delivery, ChemTech and Hercon Labs, which were both acquired by other companies. Prior to these roles he served as Director of Corporate R&D for Baxter Laboratories.
Agis was a Co-Founder and has served as both President and a Trustee of the Controlled Release Society, the official professional association of drug delivery scientists, and he has been lauded by that organization for his achievements with a Recognition Award and Election as a Fellow of CRS. He is the inventor on more than 85 U.S. patents and patent applications, including those protecting the intellectual property of InteguRx. He has contributed over 30 book chapters in drug delivery and more than 125 journal articles and abstracts.
Dr. Kydonieus received his Bachelor of Science and Ph D, both in Chemical Engineering, from the University of Florida.
Recognitions and Awards
2022 Catalyst Seed R&D Award- Granted by The Commission on Science, Innovation & Technology, a Division of The New Jersey Economic Development Authority for the further development of our apixaban transdermal patch for the treatment of Non-Valvular Atrial Fibrillation.
2023 Maternal and Infant Health R&D Award- Granted by The Commission on Science, Innovation & Technology, a Division of The New Jersey Economic Development Authority for the further development of our ondansetron transdermal patch for the treatment of Pregnancy-Induced Nausea and Vomiting.
